IG Markets Partner Tweets (Powered By Twitter)

RT IG: Nike just guided full year earnings to $1.15 to $1.35 a share, well below the $1.61 consensus, another profit warning. The team…

RT IG: One of the biggest mistakes traders make: running losses into oblivion because of ego, thinking they're right and the market's w…

RT IG: Nike trades on a seemingly expensive 25 times earnings. But its confirmed $2.5 billion Pace cost savings plan could push earning…

Regeneron makes $14 billion a year, is profitable, trades on 12 times earnings. Moderna makes almost nothing and was recently valued higher. Rich and Piers explains why they’re short the stock, and why even good trial data might not be enough to hold the price up. Fascinated to see how this plays out, are you watching this one? Full episode: youtu.be/KvA3_wMeaIA

Bond yields are hurting parts of the market, but AI equities are shrugging it off completely and hitting new highs. The team’s scoreline so far: AI one, bond market nil. How long do you think that lasts? Full episode: youtu.be/HYMmAVKabPc https://t.co/Nwu0RjM0bk

RT IG: Nike just guided full year earnings to $1.15 to $1.35 a share, well below the $1.61 consensus, another profit warning. The team…

RT IG: One of the biggest mistakes traders make: running losses into oblivion because of ego, thinking they're right and the market's w…

RT IG: Nike trades on a seemingly expensive 25 times earnings. But its confirmed $2.5 billion Pace cost savings plan could push earning…

Accused in the comments of being "paralysed" over a market collapse that never happened. The team's response: you never let the market, or the comments section, goad you into moving before you're ready. Fair criticism, or are they right to stay patient? Full episode: youtu.be/N-QrsVhJy1k

Accused in the comments of being "paralysed" over a market collapse that never happened. The team's response: you never let the market, or the comments section, goad you into moving before you're ready. Fair criticism, or are they right to stay patient? Full episode: youtu.be/N-QrsVhJy1k

Moderna doesn't make any money, but it's the most talked about stock in retail forums right now. Keytruda, the biggest cancer drug on the market, made $31.7 billion last year. Even a generous estimate for Moderna's melanoma drug lands around $100 a share. What's your read on the hype here? Full episode: youtu.be/F7UUhc6h4GM

Everyone around the table is saying "sell everything," but the team's charts tell a different story, S&P looking like it takes out the highs, Nasdaq with more room to run. Meanwhile they're eyeing a sell on Russell to fund a move into gold. Who do you believe here? Full episode: youtu.be/N-QrsVhJy1k

Rate rises will hurt Russell 2000 and FTSE 250 eventually, but one of the team says he's not selling a single thing, he wants to buy more. Meanwhile the strategist is telling him to hold more cash. Who do you side with here? Full episode: youtu.be/N-QrsVhJy1k https://t.co/eV8Vfhp0Jj

Banks and insurance companies rely on you being too lazy to switch, forms, paperwork, hassle. Rich and Piers explain why an AI agent that fills in those forms for you could quietly destroy that entire business model. Do you think this narrative holds up? Full episode: youtu.be/F7UUhc6h4GM

Meta needed $30 billion for AI data centers but didn't want it on their balance sheet. A special purpose vehicle, PIMCO, BlackRock and a firm called Blue Owl made that happen. Crystal clean balance sheet. Full episode: youtu.be/F7UUhc6h4GM https://t.co/wrTTpJifOA